Grove Bank & Trust Has $727,000 Holdings in Zoetis Inc. $ZTS

Grove Bank & Trust decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 65.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,778 shares of the company’s stock after selling 11,031 shares during the quarter. Grove Bank & Trust’s holdings in Zoetis were worth $727,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Gryphon Financial Partners LLC boosted its position in shares of Zoetis by 10.1% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,650 shares of the company’s stock valued at $333,000 after buying an additional 244 shares during the last quarter. Nordea Investment Management AB raised its position in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Aventura Private Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at $64,000. Sagespring Wealth Partners LLC lifted its stake in Zoetis by 23.9% during the 4th quarter. Sagespring Wealth Partners LLC now owns 3,040 shares of the company’s stock valued at $382,000 after acquiring an additional 586 shares in the last quarter. Finally, Precedent Wealth Partners LLC lifted its stake in Zoetis by 4.6% during the 4th quarter. Precedent Wealth Partners LLC now owns 9,792 shares of the company’s stock valued at $1,232,000 after acquiring an additional 432 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.5%

Shares of Zoetis stock opened at $115.43 on Friday. The firm has a market cap of $48.73 billion, a PE ratio of 19.17, a P/E/G ratio of 1.77 and a beta of 0.95. Zoetis Inc. has a 1 year low of $114.36 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock has a fifty day moving average price of $124.35 and a 200-day moving average price of $130.44.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analysts Set New Price Targets

Several analysts have recently issued reports on ZTS shares. Barclays started coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. UBS Group set a $136.00 price objective on shares of Zoetis in a research note on Thursday, January 29th. Finally, Bank of America lifted their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.